Ken Griffin Vertex Pharmaceuticals Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $34.1 Million - $37.5 Million	74,100 Added 54.73%	209,500 $97.4 Million
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $5.34 Million - $6.6 Million	-13,600 Reduced 9.13%	135,400 $63.5 Million
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $15.7 Million - $17.2 Million	-38,500 Reduced 20.53%	149,000 $62.3 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $16 Million - $19.2 Million	46,700 Added 33.17%	187,500 $76.3 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $9.94 Million - $10.7 Million	29,400 Added 26.39%	140,800 $49 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $4.24 Million - $4.75 Million	-13,500 Reduced 10.81%	111,400 $39.2 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $21 Million - $24 Million	-74,200 Reduced 37.27%	124,900 $39.4 Million
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $34.3 Million - $38.6 Million	-120,000 Reduced 37.61%	199,100 $57.5 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $27.9 Million - $31.2 Million	-102,000 Reduced 24.22%	319,100 $92.4 Million

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.